Arkolith/Insider Trading/TEVA/Form 4

Lippman Evan

EVP, Business DevelopmentTEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) · full profile →Form 4 · filed May 18, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.5M
Net Open-Market Flow
-$1.5M
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 14, 2026Option exercise(M)12K——12K
May 14, 2026Sell(S)6K$35.58$204K6K
May 14, 2026Option exercise(M)74K——80K
May 14, 2026Sell(S)36K$35.58$1.3M44K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 14, 2026Option exercise(M)12K—$036K
May 14, 2026Option exercise(M)74K—$074K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-228876) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML